Novel strategy for characterizing the metabolism of GSH–enal adducts in myocardial ischemia rat model using UHPLC–MS

Jialong Jing; Ning Sheng; Zhe Wang; Jinlan Zhang

doi:10.1016/j.jpha.2026.101638

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2026 > Accepted Manu

Jialong Jing, Ning Sheng, Zhe Wang, Jinlan Zhang. Novel strategy for characterizing the metabolism of GSH–enal adducts in myocardial ischemia rat model using UHPLC–MS[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2026.101638

Citation:

Jialong Jing, Ning Sheng, Zhe Wang, Jinlan Zhang. Novel strategy for characterizing the metabolism of GSH–enal adducts in myocardial ischemia rat model using UHPLC–MS[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2026.101638

Citation:

PDF( 10494 KB)

Novel strategy for characterizing the metabolism of GSH–enal adducts in myocardial ischemia rat model using UHPLC–MS

doi: 10.1016/j.jpha.2026.101638

State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China

Funds:

We gratefully acknowledge financial support from the Beijing Natural Science Foundation (Grant No.: L246027) and the CAMS Innovation Fund for Medical Sciences (Grant No.: 2024–I2M–ZH–012).

Received Date: Nov. 03, 2025
Accepted Date: Apr. 15, 2026
Rev Recd Date: Apr. 14, 2026
Available Online: Apr. 18, 2026

Abstract

Abstract

α,β-Unsaturated aldehydes (enals) are primarily metabolized via glutathione (GSH) conjugation, forming GSH–enal adducts, which represent the major pathway for their in vivo clearance and detoxification. These adducts undergo further metabolism to form GlyCys–enal adducts, Cys–enal adducts, and N-acetylcysteine (NAC)–enal adducts, ultimately excreted in urine. Elucidating the mechanisms by which enals undergo detoxification through GSH conjugation, metabolism, and excretion is important for understanding their roles in related diseases. However, comprehensive characterization of enal adducts remains challenging because of their structural instability and low concentrations in vivo. In this study, a novel strategy was developed to characterize the in vivo metabolism of GSH–enal adducts using liquid chromatography-mass spectrometry (LC-MS) combined with 2,4-dinitrophenylhydrazine derivatization. Characteristic fragment ions and fragmentation patterns were summarized based on 56 synthetic enal adducts analyzed by high-resolution MS. Based on the GSH–enal metabolic pathway, a database containing 4,496 predicted enal adducts was constructed to facilitate the discovery and identification of potential enal adducts. Using precursor ion scanning by LC-MS/MS integrated with the predicted database and characteristic fragment ions, 499 candidate enal adducts were initially detected in rat heart, liver, and kidney tissues. Among these, 49 novel enal adducts were further identified using dynamic multiple reaction monitoring, and 12 of the identified enal adducts were confirmed using synthetic standards. This strategy was successfully applied to dynamically profile GSH–enal adducts and their metabolites in rats with myocardial ischemia (MI), representing the first comprehensive elucidation of the detoxification and metabolic pathways of oxidative stress-induced enals. These findings provide new insights into the dynamic changes of enals and GSH–enal adducts during disease-associated oxidative damage.
- GSH–enal adducts,
- LC-MS,
- pre-column derivatization,
- dMRM,
- enal metabolism,
- myocardial ischemia

FullText(HTML)

References(46)

References

[1]	E. Taghiabadi, M. Imenshahidi, K. Abnous, et al., Protective effect of silymarin against acrolein-induced cardiotoxicity in mice, Evid. Based Complementary Altern. Med. 2012 (2012), 352091.
[2]	J.F. Stevens, C.S. Maier, Acrolein: Sources, metabolism, and biomolecular interactions relevant to human health and disease, Mol. Nutr. Food Res. 52 (2008) 7-25.
[3]	R. Takamiya, K. Uchida, T. Shibata, et al., Disruption of the structural and functional features of surfactant protein A by acrolein in cigarette smoke, Sci. Rep. 7 (2017), 8304.
[4]	I.D. Kozekov, L.V. Nechev, M.S. Moseley, et al., DNA interchain cross-links formed by acrolein and crotonaldehyde, J. Am. Chem. Soc. 125 (2003) 50-61.
[5]	Y.K. Koleva, J.C. Madden, M.T.D. Cronin, Formation of categories from structure-activity relationships to allow read-across for risk assessment: Toxicity of α, β-unsaturated carbonyl compounds, Chem. Res. Toxicol. 21 (2008) 2300-2312.
[6]	R.J. Henning, G.T. Johnson, J.P. Coyle, et al., Acrolein can cause cardiovascular disease: A review, Cardiovasc. Toxicol. 17 (2017) 227-236.
[7]	D. Liu, Y. Cheng, X. Mei, et al., Mechanisms of acrolein induces toxicity in human umbilical vein endothelial cells: Oxidative stress, DNA damage response, and apoptosis, Environ. Toxicol. 37 (2022) 708-719.
[8]	C. Chen, J. Lu, W. Peng, et al., Acrolein, an endogenous aldehyde induces Alzheimer’s disease-like pathologies in mice: A new sporadic AD animal model, Pharmacol. Res. 175 (2022), 106003.
[9]	N. Moretto, G. Volpi, F. Pastore, et al., Acrolein effects in pulmonary cells: Relevance to chronic obstructive pulmonary disease, Ann. N Y Acad. Sci. 1259 (2012) 39-46.
[10]	C. Ma, W. Zhang, J. Jing, et al., Enalomics: A mass spectrometry-based approach for profiling, identifying, and semiquantifying enals in biological samples, Anal. Chem. 97 (2025) 1507-1516.
[11]	R. Apak, A. Calokerinos, S. Gorinstein, et al., Methods to evaluate the scavenging activity of antioxidants toward reactive oxygen and nitrogen species (IUPAC Technical Report), Pure Appl. Chem. 94 (2022) 87-144.
[12]	I. Gulcin, Antioxidants: A comprehensive review, Arch. Toxicol. 99 (2025) 1893-1997.tr.
[13]	H. Sies, C. Berndt, D.P. Jones, Oxidative stress, Annu. Rev. Biochem. 86 (2017) 715-748.
[14]	M. Toraason, M.E. Luken, M. Breitenstein, et al., Comparative toxicity of allylamine and acrolein in cultured myocytes and fibroblasts from neonatal rat heart, Toxicology 56 (1989) 107-117.
[15]	J.D. Hayes, R.C. Strange, Glutathione S-transferase polymorphisms and their biological consequences, Pharmacology 61 (2000) 154-166.
[16]	M.W. Lieberman, R. Barrios, B.Z. Carter, et al., Gamma-glutamyl transpeptidase. What does the organization and expression of a multipromoter gene tell us about its functions, Am. J. Pathol. 147 (1995) 1175-1185.
[17]	C. Josch, L.O. Klotz, H. Sies, Identification of cytosolic leucyl aminopeptidase (EC 3.4.11.1) as the major cysteinylglycine-hydrolysing activity in rat liver, Biol. Chem. 384 (2003): 213-218.
[18]	K.C. Heathcote, T.P. Keeley, M. Myllykoski, et al., N-terminal cysteine acetylation and oxidation patterns may define protein stability, Nat. Commun. 15 (2024), 5360.
[19]	S. Tamura, H. Tsukahara, M. Ueno, et al., Evaluation of a urinary multi-parameter biomarker set for oxidative stress in children, adolescents and young adults, Free. Radic. Res. 40 (2006) 1198-1205.
[20]	X. Feng, R. Liang, D. Shi, et al., Urinary acrolein metabolites, systemic inflammation, and blood lipids: Results from the National Health and Nutrition Examination Survey, Chemosphere 286 (2022), 131791.
[21]	C.M. Dieckhaus, C.L. Fernandez-Metzler, R. King, et al., Negative ion tandem mass spectrometry for the detection of glutathione conjugates, Chem. Res. Toxicol. 18 (2005) 630-638.
[22]	S. Horiyama, M. Hatai, Y. Takahashi, et al., Intracellular metabolism of α, β-unsaturated carbonyl compounds, acrolein, crotonaldehyde and methyl vinyl ketone, active toxicants in cigarette smoke: Participation of glutathione conjugation ability and aldehyde-ketone sensitive reductase activity, Chem. Pharm. Bull. 64 (2016) 585-593.
[23]	M. Hatai, S. Horiyama, N. Yoshikawa, et al., trans-2-pentenal, an active compound in cigarette smoke, identified via its ability to form adducts with glutathione, Chem. Pharm. Bull. 67 (2019) 1000-1005.
[24]	P. Krenek, J. Kmecova, D. Kucerova, et al., Isoproterenol-induced heart failure in the rat is associated with nitric oxide-dependent functional alterations of cardiac function, Eur. J. Heart Fail. 11 (2009) 140-146.
[25]	N. Funasaki, S. Hada, S. Neya, Prediction of retention times in reversed-phase high-performance liquid chromatography from the chemical structure, J. Chromatogr. A 361 (1986) 33-45.
[26]	The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), M10 bioanalytical method validation and study sample analysis. https://database.ich.org/sites/default/files/M10_Guideline_Step4_2022_0524.pdf (Accessed 8 January 2026).
[27]	L.W. Sumner, A. Amberg, D. Barrett, et al., Proposed minimum reporting standards for chemical analysis, Metabolomics 3 (2007) 211-221.
[28]	S.D. Prabhu, N.G. Frangogiannis, The biological basis for cardiac repair after myocardial infarction: From inflammation to fibrosis, Circ. Res. 119 (2016) 91-112.
[29]	C. Kuppe, R.O. Ramirez Flores, Z. Li, et al., Spatial multi-omic map of human myocardial infarction, Nature 608 (2022) 766-777.
[30]	H. Sies, D.P. Jones, Reactive oxygen species (ROS) as pleiotropic physiological signalling agents, Nat. Rev. Mol. Cell Biol. 21 (2020) 363-383.
[31]	E. Dubois-Deruy, V. Peugnet, A. Turkieh, et al., Oxidative stress in cardiovascular diseases, Antioxidants 9 (2020), 864.
[32]	H. Zhang, H.J. Forman, 4-hydroxynonenal-mediated signaling and aging, Free. Radic. Biol. Med. 111 (2017) 219-225.
[33]	H.J. Forman, H. Zhang, Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy, Nat. Rev. Drug Discov. 20 (2021) 689-709.
[34]	H. Karagecili, M.A. Yilmaz, A. Erturk, et al., Comprehensive metabolite profiling of berdav Propolis using LC-MS/MS: Determination of antioxidant, anticholinergic, antiglaucoma, and antidiabetic effects, Molecules 28 (2023), 1739.
[35]	I. Gulcin, Antioxidants: Current summary, Balkan Med. J. (2025): 388-392.tr.
[36]	A. Negre-Salvayre, C. Coatrieux, C. Ingueneau, et al., Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors, Br. J. Pharmacol. 153 (2008) 6-20.
[37]	M.K. Mohammad, D. Avila, J. Zhang, et al., Acrolein cytotoxicity in hepatocytes involves endoplasmic reticulum stress, mitochondrial dysfunction and oxidative stress, Toxicol. Appl. Pharmacol. 265 (2012) 73-82.
[38]	J.L. Sklar, P.G. Anderson, P.J. Boor, Allylamine and acrolein toxicity in perfused rat hearts, Toxicol. Appl. Pharmacol. 107 (1991) 535-544.
[39]	C.S. Yarian, I. Rebrin, R.S. Sohal, Aconitase and ATP synthase are targets of malondialdehyde modification and undergo an age-related decrease in activity in mouse heart mitochondria, Biochem. Biophys. Res. Commun. 330 (2005) 151-156.
[40]	L. Jin, P. Lorkiewicz, Z. Xie, et al., Acrolein but not its metabolite, 3-Hydroxypropylmercapturic acid (3HPMA), activates vascular transient receptor potential Ankyrin-1 (TRPA1): Physiological to toxicological implications, Toxicol. Appl. Pharmacol. 426 (2021), 115647.
[41]	D.J. Conklin, P. Haberzettl, G. Jagatheesan, et al., Role of TRPA1 in acute cardiopulmonary toxicity of inhaled acrolein, Toxicol. Appl. Pharmacol. 324 (2017) 61-72.
[42]	D.M. Bautista, S.E. Jordt, T. Nikai, et al., TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents, Cell 124 (2006) 1269-1282.
[43]	G. Pozsgai, J.V. Bodkin, R. Graepel, et al., Evidence for the pathophysiological relevance of TRPA1 receptors in the cardiovascular system in vivo, Cardiovasc. Res. 87 (2010) 760-768.
[44]	D.Y. Mitchell, D.R. Petersen, Metabolism of the glutathione-acrolein adduct, S-(2-aldehydo-ethyl)glutathione, by rat liver alcohol and aldehyde dehydrogenase, J. Pharmacol. Exp. Ther. 251 (1989) 193-198.
[45]	N. Traverso, S. Menini, P. Odetti, et al., Diabetes impairs the enzymatic disposal of 4-hydroxynonenal in rat liver, Free. Radic. Biol. Med. 32 (2002) 350-359.
[46]	W. Draminski, E. Eder, D. Henschler, A new pathway of acrolein metabolism in rats, Arch. Toxicol. 52 (1983) 243-247.